Table 2.
Progressive Loss of Maxima ③, ④, and ⑤ of the ENOX Activity Cycle of Recombinant ENOX2 Upon Treatment With 50 nM ME-143 Based on Analyses of DTDP Cleavage Assays (Average of Five Experiments ± Standard Deviations)
| Control | 10 µM ME-143 | |||||
|---|---|---|---|---|---|---|
| (µmol/min/mg/protein) | (µmol/min/mg/protein) | |||||
| ③ | ④ | ⑤ | ③ | ④ | ⑤ | |
| Period 1 | 0.92 ± 0.30 | 0.92 ± 0.18 | 0.92 ± 0.24 | 0.80 ± 0.34 | 0.62 ± 0.20 | 0.84 ± 0.20 |
| Period 2 | 0.80 ± 0.14 | 0.90 ± 0.24 | 0.80 ± 0.22 | 0.66 ± 0.12 | 0.70 ± 0.08 | 0.34 ± 0.08 |
| Period 3 | 0.76 ± 0.06 | 0.76 ± 0.06 | 0.76 ± 0.06 | 0.48 ± 0.10 | 0.34 ± 0.10 | 0.30 ± 0.10 |
| Period 4 | 0.76 ± 0.12 | 0.70 ± 0.06 | 0.72 ± 0.06 | 0.24 ± 0.12 | 0.17 ± 0.03 | 0.28 ± 0.06 |